Market Cap 139.21B
Revenue (ttm) 22.60B
Net Income (ttm) 2.99B
EPS (ttm) N/A
PE Ratio 27.79
Forward PE 27.00
Profit Margin 13.25%
Debt to Equity Ratio 0.76
Volume 1,415,600
Avg Vol 1,622,436
Day's Range N/A - N/A
Shares Out 382.42M
Stochastic %K 14%
Beta 0.89
Analysts Strong Sell
Price Target $434.32

Company Profile

Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the t...

Industry: Medical Devices
Sector: Healthcare
Phone: (269) 385-2600
Fax: (269) 385-1062
Address:
1941 Stryker Way, Portage, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:26 AM
$SYK Actionable Trade Alert: Market Context: With the last close at $364.35, $SYK is currently trading below its 30-day ($366.67) and 50-day ($368.43) moving averages, indicating a bearish short-term trend. The RSI at 40.92 suggests the stock is nearing oversold territory, which could signal a potential reversal. Directional Bias: Given the current RSI and the proximity to the 60D low of $349.16, there is a possibility for a bounce back towards higher levels. However, caution is warranted as the stock remains below key moving averages. Trade Plan: - Suggested Entry: $365.00 - Stop Loss: $358.00 (approx. 2% risk) - Take Profit Targets: 1. TP1: $375.00 (2.73% gain) 2. TP2: $385.00 (5.73% gain) 3. TP3: $427.00 (17.25% gain) This plan allows for a favorable risk-reward ratio, targeting a significant return on TP3 while managing risk effectively. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 4 at 4:39 PM
Jefferies⬆️ $AXGN's PT to $36 from $29 and reiterated at a Buy rating $SYK $BAX IART MDGX Mizuho reiterated at Outperform/$40 Raymond James⬆️PT to $36 from $27 and reiterated at an Outperform rating Citizens reiterated at a Market Outperform/$34 Here's what the Analysts had to say in their notes to investors:
0 · Reply
Ro_Patel
Ro_Patel Dec. 4 at 3:59 PM
BofA: Surgical robot market could grow steadily over the next decade, potentially driven by: 1) robotic surgery gradually becoming the standard of care 2) rising demand for precision & shorter recovery 3) next-generation technologies – such as remote surgery 4) greater robot autonomy to enhance surgeon’s efficiency 5) expansion into new disease areas to address unmet demand. In fact, BofA Global Research expects the global surgical robot market to reach $23B in FY25 & expand to $52B by FY30 $ISRG $MDT $SYK $ZBH --- IMHO Demand: 1) Aging population 2) Less invasive surgery 3) Hospital efficiency needs
0 · Reply
SparkyReturns
SparkyReturns Dec. 2 at 7:05 PM
$ICU Zero adverse events in any study, ever. The FDA has granted them 6 Breakthrough Device Designations, meaning 6 indications with fast track. Their device calms hyperinflammation and could have very broad application from Acute Kidney Infection to Sepsis to Cardio-renal disease to helping burn victims. Areva/military also studying. Received 2 grants and awards from National Kidney Foundation, other organizations. Will become standard of care right along antibiotics with cytokine storm cases, ARDS, severe Covid, etc. Insane opportunity of a lifetime. Multi-billion dollar TAM, upwards of 10B-20B TAM. Big players like Fresenius, Davita, Baxter, Stryker or McKesson may want to get involved with Distribution to all hospitals. GL! $MCK $DVA $BAX $SYK
0 · Reply
Quantumup
Quantumup Dec. 1 at 12:18 PM
Mizuho🏁 $AXGN Outperform/$40 $SYK $BAX $IART $MDXG Mizuho said—Our OP rating on AXGN is predicated on: 1) favorable setup into the upcoming BLA PDUFA date (Dec 5) where we expect a positive outcome, 2) core extremity channel checks that point toward a potential +10% uplift in Avance utilization post-BLA approval, 3) Mizuho Americas November 2025 breast survey findings that forecasts Avance mix in reconstruction surgeries to increase +30% over the next two years, 4) untapped upside opportunity in breast augmentation where nerve injury incidence sits in 10-15% range, and 5) attractive call option in prostate cancer that could drive +$100MN of incremental peak sales (+35% uplift to 2026 base). Our $40 PT prices AXGN shares at 5.0x our blended 2-year sales outlook ('26E-'27E) while our $50 bull case contemplates higher share-capture scenarios in Breast & Prostate.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 28 at 9:40 PM
$SYK Current Stock Price: $371.89 Contracts to trade: $370 SYK Dec 19 2025 Call Entry: $8.30 Exit: $13.08 ROI: 58% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 27 at 11:12 AM
$SYK Share Price: $372.28 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $23.46 – $28.98 Target Zone: $37.97 – $46.41 Potential Upside: 53% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
rich54
rich54 Nov. 26 at 3:22 PM
$MBOT The commercialization of their approved platform just began. Easy double from here in such a biotech bull mkt. $SYK Stryker has to buy them. No other way about it. Stryker survives on acquisitions. They acquire 2-4 companies a year. $CRMD $CTXR $IBB
2 · Reply
DavyDaveCharts
DavyDaveCharts Nov. 24 at 9:39 PM
$SYK weekly: breach of the AD channel.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 20 at 7:55 PM
$SYK Share Price: $361.64 Contract Selected: Mar 20, 2026 $360 Calls Buy Zone: $17.25 – $21.32 Target Zone: $31.73 – $38.78 Potential Upside: 74% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on SYK
Stryker Corporation (SYK) Analyst/Investor Day Transcript

Nov 19, 2025, 6:03 PM EST - 17 days ago

Stryker Corporation (SYK) Analyst/Investor Day Transcript


Why Stryker Stock May Be Headed For A Prolonged Slowdown

Nov 17, 2025, 7:48 AM EST - 19 days ago

Why Stryker Stock May Be Headed For A Prolonged Slowdown


Stryker: Strong Growth, But Valuation Is A Concern

Nov 4, 2025, 10:22 PM EST - 4 weeks ago

Stryker: Strong Growth, But Valuation Is A Concern


Stryker: Striking Again

Nov 3, 2025, 4:30 AM EST - 4 weeks ago

Stryker: Striking Again


Stryker Corporation (SYK) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:16 PM EDT - 5 weeks ago

Stryker Corporation (SYK) Q3 2025 Earnings Call Transcript


Stryker raises lower end of annual profit forecast

Oct 30, 2025, 7:04 PM EDT - 5 weeks ago

Stryker raises lower end of annual profit forecast


Stryker reports third quarter 2025 operating results

Oct 30, 2025, 4:05 PM EDT - 5 weeks ago

Stryker reports third quarter 2025 operating results


Stryker Launches Incompass Total Ankle System at AOFAS 2025

Sep 9, 2025, 7:20 AM EDT - 3 months ago

Stryker Launches Incompass Total Ankle System at AOFAS 2025


Stryker Q2: Record Mako Installation And High Utilization

Aug 19, 2025, 2:55 PM EDT - 3 months ago

Stryker Q2: Record Mako Installation And High Utilization


Stryker to host investor day

Aug 15, 2025, 8:00 AM EDT - 4 months ago

Stryker to host investor day


Stryker declares an $0.84 per share quarterly dividend

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Stryker declares an $0.84 per share quarterly dividend


Stryker (SYK) Q2 Revenue Jumps 11%

Aug 2, 2025, 5:08 AM EDT - 4 months ago

Stryker (SYK) Q2 Revenue Jumps 11%


Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:59 PM EDT - 4 months ago

Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript


Stryker reports second quarter 2025 operating results

Jul 31, 2025, 4:05 PM EDT - 4 months ago

Stryker reports second quarter 2025 operating results


The Big 3: NXT, ANET, SYK

Jun 26, 2025, 1:01 PM EDT - 5 months ago

The Big 3: NXT, ANET, SYK

ANET NXT


Stryker receives FDA clearance for Incompass Total Ankle System

Jun 25, 2025, 8:15 AM EDT - 5 months ago

Stryker receives FDA clearance for Incompass Total Ankle System


The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

Jun 3, 2025, 11:09 AM EDT - 6 months ago

The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

MA NFLX


Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:28 PM EDT - 7 months ago

Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript


Stryker reports first quarter 2025 operating results

May 1, 2025, 4:05 PM EDT - 7 months ago

Stryker reports first quarter 2025 operating results


Stryker completes sale of U.S. spinal implants business

Apr 1, 2025, 4:05 PM EDT - 8 months ago

Stryker completes sale of U.S. spinal implants business


Stryker announces Annual Meeting of Shareholders

Mar 25, 2025, 4:15 PM EDT - 9 months ago

Stryker announces Annual Meeting of Shareholders


The Big 3: MMM, PM, SYK

Mar 18, 2025, 1:01 PM EDT - 9 months ago

The Big 3: MMM, PM, SYK

MMM PM


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:26 AM
$SYK Actionable Trade Alert: Market Context: With the last close at $364.35, $SYK is currently trading below its 30-day ($366.67) and 50-day ($368.43) moving averages, indicating a bearish short-term trend. The RSI at 40.92 suggests the stock is nearing oversold territory, which could signal a potential reversal. Directional Bias: Given the current RSI and the proximity to the 60D low of $349.16, there is a possibility for a bounce back towards higher levels. However, caution is warranted as the stock remains below key moving averages. Trade Plan: - Suggested Entry: $365.00 - Stop Loss: $358.00 (approx. 2% risk) - Take Profit Targets: 1. TP1: $375.00 (2.73% gain) 2. TP2: $385.00 (5.73% gain) 3. TP3: $427.00 (17.25% gain) This plan allows for a favorable risk-reward ratio, targeting a significant return on TP3 while managing risk effectively. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Dec. 4 at 4:39 PM
Jefferies⬆️ $AXGN's PT to $36 from $29 and reiterated at a Buy rating $SYK $BAX IART MDGX Mizuho reiterated at Outperform/$40 Raymond James⬆️PT to $36 from $27 and reiterated at an Outperform rating Citizens reiterated at a Market Outperform/$34 Here's what the Analysts had to say in their notes to investors:
0 · Reply
Ro_Patel
Ro_Patel Dec. 4 at 3:59 PM
BofA: Surgical robot market could grow steadily over the next decade, potentially driven by: 1) robotic surgery gradually becoming the standard of care 2) rising demand for precision & shorter recovery 3) next-generation technologies – such as remote surgery 4) greater robot autonomy to enhance surgeon’s efficiency 5) expansion into new disease areas to address unmet demand. In fact, BofA Global Research expects the global surgical robot market to reach $23B in FY25 & expand to $52B by FY30 $ISRG $MDT $SYK $ZBH --- IMHO Demand: 1) Aging population 2) Less invasive surgery 3) Hospital efficiency needs
0 · Reply
SparkyReturns
SparkyReturns Dec. 2 at 7:05 PM
$ICU Zero adverse events in any study, ever. The FDA has granted them 6 Breakthrough Device Designations, meaning 6 indications with fast track. Their device calms hyperinflammation and could have very broad application from Acute Kidney Infection to Sepsis to Cardio-renal disease to helping burn victims. Areva/military also studying. Received 2 grants and awards from National Kidney Foundation, other organizations. Will become standard of care right along antibiotics with cytokine storm cases, ARDS, severe Covid, etc. Insane opportunity of a lifetime. Multi-billion dollar TAM, upwards of 10B-20B TAM. Big players like Fresenius, Davita, Baxter, Stryker or McKesson may want to get involved with Distribution to all hospitals. GL! $MCK $DVA $BAX $SYK
0 · Reply
Quantumup
Quantumup Dec. 1 at 12:18 PM
Mizuho🏁 $AXGN Outperform/$40 $SYK $BAX $IART $MDXG Mizuho said—Our OP rating on AXGN is predicated on: 1) favorable setup into the upcoming BLA PDUFA date (Dec 5) where we expect a positive outcome, 2) core extremity channel checks that point toward a potential +10% uplift in Avance utilization post-BLA approval, 3) Mizuho Americas November 2025 breast survey findings that forecasts Avance mix in reconstruction surgeries to increase +30% over the next two years, 4) untapped upside opportunity in breast augmentation where nerve injury incidence sits in 10-15% range, and 5) attractive call option in prostate cancer that could drive +$100MN of incremental peak sales (+35% uplift to 2026 base). Our $40 PT prices AXGN shares at 5.0x our blended 2-year sales outlook ('26E-'27E) while our $50 bull case contemplates higher share-capture scenarios in Breast & Prostate.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 28 at 9:40 PM
$SYK Current Stock Price: $371.89 Contracts to trade: $370 SYK Dec 19 2025 Call Entry: $8.30 Exit: $13.08 ROI: 58% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 27 at 11:12 AM
$SYK Share Price: $372.28 Contract Selected: Jun 18, 2026 $370 Calls Buy Zone: $23.46 – $28.98 Target Zone: $37.97 – $46.41 Potential Upside: 53% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
rich54
rich54 Nov. 26 at 3:22 PM
$MBOT The commercialization of their approved platform just began. Easy double from here in such a biotech bull mkt. $SYK Stryker has to buy them. No other way about it. Stryker survives on acquisitions. They acquire 2-4 companies a year. $CRMD $CTXR $IBB
2 · Reply
DavyDaveCharts
DavyDaveCharts Nov. 24 at 9:39 PM
$SYK weekly: breach of the AD channel.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 20 at 7:55 PM
$SYK Share Price: $361.64 Contract Selected: Mar 20, 2026 $360 Calls Buy Zone: $17.25 – $21.32 Target Zone: $31.73 – $38.78 Potential Upside: 74% ROI Time to Expiration: 119 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
arvinsusanna
arvinsusanna Nov. 19 at 4:06 AM
$OPEN $PTTO $LOW $SYK The slope of the ascent has steepened, entering a fast track. https://stocktwits.com/alancarey/message/636687263
0 · Reply
groverwat
groverwat Nov. 19 at 2:39 AM
$OPEN $PTTO $LOW $SYK The slope of the ascent has steepened, entering a fast track. https://stocktwits.com/abnerhousman/message/636682752
0 · Reply
thelattehq
thelattehq Nov. 16 at 4:01 PM
$NVDA $NTRA $SYK https://www.thelattehq.com/p/a-market-looking-for-direction
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 5:59 PM
Truist Securities has updated their rating for Stryker ( $SYK ) to Hold with a price target of 400.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 3:17 PM
Wells Fargo updates rating for Stryker ( $SYK ) to Overweight, target set at 452 → 456.
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 10:40 AM
Needham has updated their rating for Stryker ( $SYK ) to Buy with a price target of 448.
0 · Reply
anachartanalyst
anachartanalyst Nov. 14 at 10:05 AM
$SYK https://anachart.com/wp-content/uploads/ana_temp/1763114709_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 10:01 AM
BTIG has adjusted their stance on Stryker ( $SYK ), setting the rating to Buy with a target price of 410.
0 · Reply
JustinThomas460
JustinThomas460 Nov. 12 at 3:06 PM
$SYK drives medical-device innovation with steady revenue growth and leadership in orthopedic and surgical technologies. AERT recently turned profitable in Q2 FY2026, reporting $17.36 M revenue and $0.64 M net income, highlighting momentum in its AI-led global delivery model. https://www.youtube.com/watch?v=d2BieklTnl4
0 · Reply
TalkMarkets
TalkMarkets Nov. 11 at 1:48 AM
SYK: A Medical Equipment Maker Benefiting From M&A, New Products $SYK https://talkmarkets.com/content/stocks--equities/syk-a-medical-equipment-maker-benefiting-from-ma-new-products?post=535562
0 · Reply
Sibert52
Sibert52 Nov. 10 at 12:50 AM
$SYK https://www.marketbeat.com/instant-alerts/filing-stryker-corporation-syk-shares-acquired-by-wedbush-securities-inc-2025-11-08/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 11:11 PM
0 · Reply